List of Juvisync drug patents
Juvisync is owned by Merck Sharp Dohme.
Juvisync contains Simvastatin; Sitagliptin Phosphate.
Juvisync has a total of 7 drug patents out of which 5 drug patents have expired.
Expired drug patents of Juvisync are:
- US8168637
- US7125873
- US6699871*PED
- US7125873*PED
- US6699871
Juvisync was authorised for market use on 07 October, 2011.
Juvisync is available in tablet;oral dosage forms.
Juvisync can be used as method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with a ppar-gamma agonist (such as pioglitazone and rosiglitazone); method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with a sulfonylurea (such as glipizide, glimepiride and glyburide); method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with metformin; method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with insulin, method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate.
The generics of Juvisync are possible to be released after 11 October, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168637 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes |
Jun, 2022
(7 months ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) | |
|
US6699871
(Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(10 days ago) | |
|
US7125873
(Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(10 days ago) | |
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Oct, 2026
(3 years from now) | |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate; Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with a ppar-gamma agonist (such as pioglitazone and rosiglitazone); Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with a sulfonylurea (such as glipizide, glimepiride and glyburide); Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with metformin; Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with insulin
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic